| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2021 , Vol 59 , Num 4
Review Article: Pitavastatin: Similarities and Differences Compared With Other Statins
1 Catedra de Riesgo Cardiovascular, Universidad de Salamanca, Salamanca, Spain2 Department of Internal Medicine, Kartal Research and Education Hospital, Istanbul, Turkey
3 Department of Medical Pharmacology, Beykent University- Beykent Faculty of Medicine, Istanbul, Turkey
4 Department of Cardiology, Kelkit State Hospital, Gumushane, Turkey
5 Department of Cardiology, University of Sciences and Research Hospital, Istanbul, Turkey
6 Hospital Universitario de Badajoz. Badajoz. Spain
DOI : 10.23893/1307-2080.APS.05935 Viewed : 15155 - Downloaded : 3773 Dyslipidemia is the leading cause of cardiovascular mortality and morbidity. Reduction of lipids, particularly low- density lipoprotein cholesterol (LDL-C), with statins, significantly decreases the risk of cardiovascular events. Among different statins, pitavastatin, exhibits a peculiar pharmacokinetic and pharmacological profile. Indeed, differently from other statins, pitavastatin: a) is not metabolized by hepatic cytochrome CYP3A4 isoenzyme, therefore has a very low drug-drug interaction; b) has a similar or greater effect on LDL-C, c) is not associated with glucose metabolism impairment, and the risk of new onset diabetes is very low, d) increases high density lipoproteins (HDL) levels and, particularly, improves cholesterol efflux capacity of HDL, d) decreases cardiovascular outcome in primary and secondary prevention. Keywords : Dyslipidemia, statins, pitavastatin, new-onset diabetes, HDL